Health and economic outcomes for exenatide once weekly, insulin, and pioglitazone therapies in the treatment of type 2 diabetes: a simulation analysis

BACKGROUND: Patients with type 2 diabetes (T2DM) are at risk of long-term vascular complications. In trials, exenatide once weekly (ExQW), a GLP-1R agonist, improved glycemia, weight, blood pressure (BP), and lipids in patients with T2DM. We simulated potential effects of ExQW on vascular complicati...

Descripción completa

Detalles Bibliográficos
Autores principales: Gaebler, Julia A, Soto-Campos, Gerardo, Alperin, Peter, Cohen, Marc, Blickensderfer, Amy, Wintle, Matthew, Maggs, David, Hoogwerf, Byron, Han, Jenny, Pencek, Richard, Peskin, Barbara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2012
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3346268/
https://www.ncbi.nlm.nih.gov/pubmed/22566747
http://dx.doi.org/10.2147/VHRM.S28744

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3346268/
https://www.ncbi.nlm.nih.gov/pubmed/22566747
http://dx.doi.org/10.2147/VHRM.S28744

Ejemplares similares